(function(doc, html, url) { var widget = doc.createElement("div"); widget.innerHTML = html; var script = doc.currentScript; // e = a.currentScript; if (!script) { var scripts = doc.scripts; for (var i = 0; i < scripts.length; ++i) { script = scripts[i]; if (script.src && script.src.indexOf(url) != -1) break; } } script.parentElement.replaceChild(widget, script); }(document, '

What is it about?

Long-acting antipsychotics are recognized as a valuable option for preventing relapse in people with schizophrenia, however, there is uncertainty on which of these medications are the most effective and acceptable. This network meta-analysis included 78 randomized trials (comprising 11,505 individuals) in order to compare long-acting antipsychotics between each other. Most of them showed a similar profile, however, those supported by the most reliable data in terms of both relapse prevention and all-cause treatment discontinuation (indicated as "acceptability") were paliperidone-LAI 3- and 1-monthly, aripiprazole-LAI, and olanzapine-LAI.

Read more on Kudos…
The following have contributed to this page:
Giovanni Ostuzzi
' ,"url"));